Advanced Hyperbaric Oxygen Services

How your hospital will benefit from our Hyperbaric Medicine Program

LST can provide complete hyperbaric services, with or without wound care, to best customize and complement your hospital operation.

What is Hyperbaric Oxygen Therapy?

Hyperbaric Oxygen Therapy (HBOT) enhances the natural healing process in the body in by increasing blood oxygen levels. Normally, only red blood cells transport oxygen throughout the body. By breathing 100% O2 under pressure inside a hyperbaric chamber, the oxygen is dissolved into all of the bod’s tissues. This assists white blood cells to fight bacteria, reduces tissue swelling, and allows new blood vessels to form, which in return helps with the formation of new healthy tissue and overall healing. HBOT is a non-invasive and painless treatment in a monoplace (single patient) or multiplace (two or more patients) hyperbaric chamber. It is an adjunctive therapy, which means it is generally part of an overall care plan, integrated with wound care, diet and other treatment.

Turnkey Hyperbaric Medicine Management, Operations and Staffing Programs

  • Optimal healing rates through integration of HBOT as adjunctive treatment
  • Increased patient compliance in state of the art, climate controlled hyperbaric chambers for patient comfort
  • We provide outpatient or inpatient programs
  • Onsite training on hyperbaric equipment; consulting for billing and administrative support
  • Application of the latest wound care technologies for best results helps both patient and facility
  • Proprietary hyperbaric and wound care reporting software for outcome tracking
  • LST staff are active members of the international UHMS, NFPA, and ASME PVHO safety committees

Indications for Hyperbaric Oxygen Therapy (HBOT) per National Government Services Medical Policy Center (MPA)

Indications and Limitations of Coverage (for complete information, please go directly to the website.)

Covered Conditions

Program reimbursement for HBO therapy will be limited to that which is administered in a chamber (including the one man unit) and is limited to the following conditions:

  1. Acute carbon monoxide intoxication,
  2. Decompression illness,
  3. Gas embolism,
  4. Gas gangrene,
  5. Acute traumatic peripheral ischemia. HBO therapy is a valuable adjunctive treatment to be used in combination with accepted standard therapeutic measures when loss of function, limb, or life is threatened.
  6. Crush injuries and suturing of severed limbs. As in the previous conditions, HBO therapy would be an adjunctive treatment when loss of function, limb, or life is threatened.
  7. Progressive necrotizing infections (necrotizing fasciitis),
  8. Acute peripheral arterial insufficiency,
  9. Preparation and preservation of compromised skin grafts (not for primary management of wounds),
  10. Chronic refractory osteomyelitis, unresponsive to conventional medical and surgical management,
  11. Osteoradionecrosis as an adjunct to conventional treatment,
  12. Soft tissue radionecrosis as an adjunct to conventional treatment,
  13. Cyanide poisoning,
  14. Actinomycosis, only as an adjunct to conventional therapy when the disease process is refractory to antibiotics and surgical treatment,
  15. Diabetic wounds of the lower extremities in patients who meet the following three criteria:
    1. Patient has type I or type II diabetes and has a lower extremity wound that is due to diabetes;
    2. Patient has a wound classified as Wagner grade III or higher; and
    3. Patient has failed an adequate course of standard wound therapy.

The use of HBO therapy is covered as adjunctive therapy only after there are no measurable signs of healing for at least 30 –days of treatment with standard wound therapy and must be used in addition to standard wound care. Standard wound care in patients with diabetic wounds includes: assessment of a patient’s vascular status and correction of any vascular problems in the affected limb if possible, optimization of nutritional status, optimization of glucose control, debridement by any means to remove devitalized tissue, maintenance of a clean, moist bed of granulation tissue with appropriate moist dressings, appropriate off-loading, and necessary treatment to resolve any infection that might be present. Failure to respond to standard wound care occurs when there are no measurable signs of healing for at least 30 consecutive days. Wounds must be evaluated at least every 30 days during administration of HBO therapy. Continued treatment with HBO therapy is not covered if measurable signs of healing have not been demonstrated within any 30-day period of treatment.